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We  have evaluated the efﬁcacy of short-interfering RNAs targeting the nucleoprotein gene
and  also the brain immune response in treated and non-treated infected mice. Mice were
inoculated with wild-type virus, classiﬁed as dog (hv2) or vampire bat (hv3) variants and
both groups were treated or leaved as controls. No difference was observed in the lethality
rate  between treated and non-treated groups, although clinical evaluation of hv2 infected
mice showed differences in the severity of clinical disease (p = 0.0006). Evaluation of brain
immune response 5 days post-inoculation in treated hv2 group showed no difference among
the  analyzed genes, whereas after 10 days post-inoculation there was increased expression
of  2′,5′-oligoadenylate synthetase 1, tumor necrosis factor alpha, interleukin 12, interferon
gamma, and C-X-C motif chemokine 10 associated with higher expression of N gene in the
same  period (p < 0.0001). In hv2 non-treated group only higher interferon beta expression was
found at day 5. The observed differences in results of the immune response genes between
treated and non-treated groups is not promising as they had neither impact on mortalitynor  even a reduction in the expression of N gene in siRNA treated animals. This ﬁnding
suggests that the use of pre-designed siRNA alone may not be useful in rabies treatment.
©  2015 Elsevier Editora Ltda. All rights reserved.
reported cases in which this protocol was tested without
3ntroduction
abies virus (RABV) causes acute encephalitis and has a case-
atality rate approaching 100% being considered one of the
ost deadly existent infectious diseases.1 The survival of a
5-year-old girl from Wisconsin, bitten by a bat that received
∗ Corresponding author at: UNESP-FMVZ-DHVSP, Distrito de Rubião Jr, s
E-mail  address: jane@fmvz.unesp.br (J. Megid).
ttp://dx.doi.org/10.1016/j.bjid.2015.05.008
413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.no vaccination, led physicians worldwide to apply the proto-
col known as the “Milwaukee Protocol”2 but after 10 years
it has been shown to be ineffective. There are at least 26em numero, Botucatu, São Paulo, CEP 18.618-970, Brazil.
success. Therefore, continuous efforts should be made to ﬁnd
some effective treatment for rabies, including new technolo-
gies such as RNA interference.
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Table 1 – Nucleotide sequences of siRNAs designed
against Pasteur virus N gene.22
siRNA Duplex sequence
RNA124 Sense 5′GCCUGAGAUUAUCGUGGAG 3′
Antisense 5′AUCCACGAUAAUCUCAGGC 3′
RNA750 Sense 5′GCACAGUUGUCACUGCUUC3′
Antisense 5′UAAGCAGUGACAACUGUGC
3′
RNA B Sense 5′GACAGCUGUUCCUCACUCG 3′454  b r a z j i n f e c t d 
RNA interference (RNAi) is an endogenous mechanism, ﬁrst
described in the late 90s that leads to post-transcriptional
gene silencing. It is well conserved in a broad variety of
species, including plants and animals.4,5 A short nucleotide
sequence (approx. 21–23 nucleotides length), also known
as short-interfering RNA (siRNA), associated with the RNA-
induced silencing complex (RISC), recognizes and binds to a
complementary mRNA, causing its cleavage into smaller frag-
ments and inactivating its expression and, thus, inhibiting
protein synthesis.6 The RNAi mechanism plays an important
role in cellular defense against viral infections in addition to
other important cellular functions, including the mobility of
genetic elements and regulation of gene expression during
animal development.7 The general potential of this mecha-
nism has stimulated studies of the use of siRNA and microRNA
as a therapeutic option for non-infectious8–10 and infectious
diseases, including dengue,11,12 respiratory syncytial virus,13
inﬂuenza,14 tuberculosis,15 SARS,16 AIDS,10 and herpes sim-
plex type 2.17
Despite the antiviral effect of siRNAs, they are potent
activators of the mammalian innate immune system. Syn-
thetic siRNA duplexes can induce high levels of inﬂammatory
cytokines and type I interferons, after systemic admin-
istration in mammals and in primary human blood cell
cultures.18,19 The production of antiviral agents such as
type I interferons, including interferon alpha (IFN) and
interferon beta (IFN), is an important immune mechanism
against rabies virus infection that occurs soon after the cell
infection.20,21
In 2007, Brandão and colleagues published a study in BHK-
21 cells showing the efﬁcacy of a novel therapy against rabies
virus based on the use of siRNAs designed against the N gene
sequence of Pasteur virus (PV). The results demonstrated that
cells treated with three different sequences of siRNA had
a ﬁve-fold drop in the amount of infected cells evaluated
by direct immunoﬂuorescence test when compared to con-
trols, with no cytopathogenicity due to the treatment.22 Those
same sequences were tested by the same group in vivo and
demonstrated reduction in the lethality rate when compared
to untreated animals.23
Studies testing siRNAs in vitro and in vivo usually have as
targets rabies nucleoprotein (N), glycoprotein (G), and/or poly-
merase (L) genes; the sequences are delivered by a vector such
as adenovirus,24 lentivirus,25 or associated with a liposome.26
siRNAs always inhibit viral replication at some level, how-
ever it is difﬁcult to precisely determine their real efﬁcacy and
possible application in medical practice. This is because in
almost all studies, the siRNAs tested are those designed and
checked in experimental infection due to exactly the same
RABV strains (usually a laboratory strain) used as templates
to design the siRNA sequences.7,22,24,26
This study aimed to test the clinical efﬁcacy of three differ-
ent sequences of siRNA designed against the RABV N gene in
the treatment of mice infected with two different wild strains
of RABV, isolated from rabid human patients infected by a dog
or by a vampire bat variant. In addition, considering the differ-
ence of pathogenicity between dog and bat variants27 and the
immune stimulation that siRNA administration can induce,
the brain immune response of infected and non-infected ani-
mals was evaluated.Antisense 5′AGAGUGAGGAACAGCUGUC
3′
Materials  and  methods
Experimental  design
Two groups of 60 C57/BL6 mice each, 4–6 week-old females,
S.P.F, were inoculated in the gastrocnemius muscle with 100 L
of viral inoculum with same viral titration (LD50 10−6.66/30 L)
for variant 2 [dog (hv2)] or variant 3 [vampire bat (hv3)]. Thirty
animals were treated intraperitoneally 24 h p.i., with a unique
dose of a mixture consisting of three siRNA sequences (3.3 M
concentration each) designed against the N gene of the PV
strain, using lipofectamine as the delivery method22 (Table 1);
the other half (n = 30) were left untreated, and just received
saline intraperitoneally at the same time of the siRNA treated
group. A non-inoculated group of animals (n = 30) were used as
controls for basal immune response and received intramus-
cular of sterile saline as well as intraperitoneal inoculation.
A non-inoculated siRNA treated group (n = 30) was included
to evaluate possible side effects of the treatment and also
the immune stimulation of siRNA. For all groups, 10 animals
were observed for 30 days and 10 were euthanized after 5 and
10 days p.i., when whole brains were removed and stored at
−80 ◦C until further real-time PCR analyses.
Animals of all groups were weighted and evaluated daily for
the onset of rabies clinical signs, such as rufﬂed fur, hunch-
ing back, hypo/hyper excitability, paralysis of one or both hind
limb or tetraplegia,28 and for any other abnormality in the case
of the non-inoculated groups.
The animal study was approved by the São Paulo State
University Ethical Committee (registration number 238/2008),
which follows the guidelines established by the COBEA –
Brazilian College of Animal Experimentation).
RNA  extraction  and  Real  Time-RT-PCR  (RT-qPCR)
Brain tissue RNAs were extracted with the Invitek® kit and
stored at −80 ◦C. The reaction for cDNA synthesis consisted
of 1 g of extracted RNA, 1 L of Oligo-DT primer (Invitrogen®)
and 1 L of SuperScript II (Invitrogen®) according to the man-
ufacturer’s instructions. The RT-qPCR reaction was performed
with 2 L of 1/50 diluted cDNA, 1 L of 0.1 g of each primer
and Master Mix Syber Green (Promega®) in a ﬁnal volume of
25 L according to the manufacturer’s instructions. Primers
for the 18S murine genes were supplied by IDT® and used
as housekeeping genes, and primers for the RABV N gene
were manufactured as described previously.29 The mouse
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Fig. 1 – (A) Lethality rate of controls and siRNA-treated groups inoculated with variant 2 (hv2) and variant 3 (hv3); Cox
proportional hazards were  used to estimate lethality rates and hazard ratios between groups. No statistical difference was
found. (B) Percentage of animals in each group showing clinical signs, which included weight loss, rufﬂed fur, hunched
back, hypoexcitability, hyperexcitability, paralysis, and tetraplegia; Kruskal–Wallis test showed a statistical difference
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period, either at 5 or 10 days p.i., showed no signiﬁcant dif-
ference. However, N gene expression in the hv2 treated group
was signiﬁcantly increased at day 10 vs day 5 p.i. (p < 0.0001).
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Fig. 2 – RABV N gene expression in the brain of mice
infected with hv2 or hv3, treated or non-treated (control)
with siRNA. Kruskal–Wallis test was applied to comparep = 0.0006) between the hv2 control and siRNA-treated group
uantitect® Primer Assay from Qiagen® was used to evalu-
te the expression of chemokine C-C motif ligand 2 (CCL2),
′-5′-oligoadenylate synthetase 1 (OAS1), interleukin 2 (IL2),
nterleukin 6 (IL6), interleukin 12 (IL12), tumor necrosis fac-
or alpha (TNF), interferon gamma (IFN), interferon beta
IFN), C-X-C motif chemokine 10 (CXCL10), cell surface gly-
oprotein CD200 receptor 1(CD200R) and insulin-like growth
actor 1 (IGF-1).
All thermal cycling and detection was performed using
n Applied Biosystems StepOne Fast (ABI7500 Fast) thermal
ycler employing a thermal proﬁle of 40 cycles of 50 ◦C for 20 s,
5 ◦C for 10 min, 95 ◦C for 15 s and 60 ◦C for 1 min.
ata  analysis
ox proportional hazards were used to estimate lethality rate
nd hazard ratios (HR) between groups. Kruskal–Wallis with
 < 0.05 as the signiﬁcance level was chosen for evaluation
f gene expression of cytokines/chemokines and the RABV
 gene. Graph-Prism® 5.0 and Instat® softwares were used
s analysis tools. Gene expression of cytokines/chemokines
ere ﬁrst compared between treated and non-treated groups
noculated with the same variant, at the same period, 5 or 10
ays p.i (ex: hv3 non-treated 5 days vs hv3 siRNA treated at 5
ays); a second comparison was made between groups at the
ame condition, inoculated (with same viral variant) treated
nd non-treated but at different periods, 5 and 10 days (ex: hv2
iRNA treated at 5 days vs hv2 siRNA treated at 10 days).
esults  and  discussionhere was a nonsigniﬁcant statistical difference in mortality
ate in the groups treated with siRNAs irrespective of the vari-
nts used. For hv2, the lethality rate was 100% in non-treated
nd 70% in treated groups (p = 0.27; HR = 0.57); for hv3, thelethality was 60% in non-treated and 80% in treated groups
(p = 0.21; HR = 1.97) (Fig. 1A).
Clinical evaluation of animals infected with variant 2 and
treated with siRNA showed less severity of clinical disease,
which included weight loss, paralysis, and death (p = 0.0006)
compared to the controls. However, no clinical difference was
observed among hv3-infected animals either treated or non-
treated with siRNA (Fig. 1B).
The N gene expression of all groups compared at the samethe results between different groups at day 5 and day 10 p.i.
There was no difference between the hv2 and hv3 groups at
day 5 or at day 10. However, hv2 siRNA-treated groups
showed a signiﬁcant difference (***p < 0.001) at 5 vs 10 days.
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Fig. 3 – Relative gene expression of cytokines and chemokines in different groups (hv2 and hv3) at day 5 and day 10 p.i. The
Kruskal–Wallis test was applied to analyze the results. (A) Expression at day 5 p.i. in the hv2 control (NT) and siRNA-treated
(T) groups; IFN was highly expressed in the NT group (***p < 0.001). (B) Expression at day 10 p.i. in the hv2 control (NT) and
siRNA-treated (T) groups; IL12 was highly expressed in the NT group (**p  < 0.01); in the treated group, OAS1, TNF˛, IL12, IFN
and CXCL10 expression levels were  increased (*p < 0.05). (C) Expression at day 5 p.i in the hv3 control (NT) and siRNA-treated
(T) groups; IFN was highly expressed in the NT group (**p  < 0.01). (D) Expression at day 10 p.i. in the hv3 control (NT) and
siRNA-treated (T) groups; no signiﬁcant difference was found.The increase in N gene expression is expected to follow dis-
ease progression.28 However, despite not reaching statistical
signiﬁcance, hv2 siRNA-treated animals at day 5 had very low
expression compared to all other groups at the same period,
reﬂecting some interference of siRNA in virus replication in
this study (Fig. 2).
The brain immune response of different groups showed
high expression of IFN- (p < 0.001) at day 5 p.i. in hv2 non-
treated group and IFN- (p < 0.01) and CCL2 (p < 0.001) in
hv3 non-treated group; at day 10 p.i. hv2 non-treated group
showed increased IL12 expression (p < 0.01). There was no sta-
tistical difference in the analyzed immune markers in the
treated hv2 group at day 5, whereas at day 10 OAS1, TNF-
, IL12, IFN-, and CXCL10 were increased (p < 0.05) (Fig. 3).
Infected cells showed a rapid production and release of IFN-,
which is important for host survival. This induces the expres-
sion of several IFN-stimulated genes (ISGs), such as OAS1,  thatexert an antiviral effect similar to IFN-, but at different stages
of viral replication.28 Damaged neurons also produce IFN-,
IL1, IL6, IL12, CCL2, CCL4, CCL5, CCL7 and the IFN-inducible
protein, CXCL10. All these cytokines and chemokines are
responsible for the upregulated expression of major histo-
compatibility complex (MHC) molecules on the surface of
microglia and also for the increased expression of adhesion
molecules by endothelial cells. All the associated factors are
important for induction of the adaptive immune response,
which involves the activation and migration of T cells, as well
as the production of speciﬁc antibodies.30–32 Enhanced N gene
expression at day 10 vs day 5 in hv2-infected mice may indi-
cate that at day 5 siRNA interfered with viral replication, which
was associated with no difference among cytokine/chemokine
gene expression at day 5 in this group (e.g., IFN-), suggesting
that viral levels were not sufﬁcient to trigger the host immune
response. This pattern of response did not occur in the hv2
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Fig. 4 – Relative expression of immune markers at days 5
and 10 in mice brains after administration of siRNAs. The
treatment led to an increase in gene expression of IFN
(*p < 0.05) at day 5. The Kruskal–Wallis test was used to
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on-treated group that showed a higher IFN- expression at
ay 5 nor in the hv3 treated group, which has a similar gene
xpression proﬁle compared to non-treated groups.
Considering the differences in the results between variant
 and 3, the identity of siRNA sequences and the bat and dog
iruses used in this study were blasted showing identity ran-
ing from 95 to 100% for hv2 and 86 to 95% for hv3. The siRNAs
ested were designed based on Paster virus (PV),22 which is a
xed strain, and the identity results indeed showed a differ-
nce between street rabies virus and siRNA sequences, with
ower identity for the bat variant.
Although the N gene is considered a conserved site, stud-
es have shown a signiﬁcant genetic variability in street rabies
irus strains, from 5 up to 49%.33,34 It is important to remem-
er that almost a perfect complementary sequence between
iRNA molecule and the viral RNA target is necessary to
nduce cleavage of mRNA.35 This requirement may explain
he difference found in the results for dog and bat variants
bserved in this study and also the lack of difference in the
 gene expression among the groups evaluated in the same
eriod.
To assess if treatment with siRNA could at least be par-
ially effective in the symptomatic phase of the disease, an
dditional study in mice was developed administering a sin-
le dose of siRNAs only after the onset of clinical signs. No
ifference in mortality, clinical evaluation, or prolongation in
he evolution period was observed in any of the treated groups
data not shown).
The immune response evaluation in non-inoculated ani-
als treated with siRNA showed an up-regulation of all
mmune markers, in particular that of IFN- at day 5 compared
o day 10. This increase disappeared at 10 days, reﬂecting the
eduction in the activity of siRNA, which can last up to 6 days36
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Conclusion
Therapy with siRNA has neither reduced the lethality rate
in two different street rabies virus infections nor N gene
expression. However, there were less severe clinical signs
using siRNA therapy in variant 2 infection. The efﬁcacy of
siRNA therapy is closely associated with the identity of the
siRNA design and its target. In this study, a higher identity
was reached with variant 2 despite variant 3, justifying the
obtained results. A reduced expression of immune markers
with siRNA therapy in infected, but not in non-infected mice,
may have occurred as a result of the antiviral effect. How-
ever, the results were not translated on reduced mortality or
expression of N gene, which can indirectly reﬂect virus repli-
cation suggesting that pre-designed siRNA may not be useful
in rabies treatment. The potential in applying this technol-
ogy is limited because in medical practice the type of virus
infecting the patient is unknown in almost 100% of the cases.
More studies are necessary to overcome this limitation and to
show whether this technology could be applied either alone
or associated with other therapeutic measures.
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